News Pharma Industry

Aurobindo Pharma: A muddled deal has scarred Aurobindo Pharma. Regaining investor confidence won’t be easy.

Courtesy of Aurobindo Pharma


Aurobindo Pharma has built a strong and diverse product pipeline to drive future growth. But corporate-governance issues and promoters’ history will be an overhang for the stock and are likely to have a bearing on investors’ perception of the second-largest pharma company in India in terms of revenue.

A deal done and undone in a jiffy has left Aurobindo Pharma in disarray. Not only has its stock been among the worst performers, the company’s reputation has also taken a beating. On August 12, Aurobindo Pharma announced its decision to acquire 51% stake in Cronus Pharma Specialities India Pvt Ltd, a company that makes veterinary pharma products, for a cash consideration of INR420 crore. On the same day, Aurobindo Pharma also reported

  • SAVE

Sign in to read the full article

You’ve got this Prime Story as a Free Gift

Already a Member?

Special Offer on ET Prime

Get Flat 20% Off


Get Offer

Why ?

  • Exclusive Economic Times Stories, Editorials & Expert opinion across 20+ sectors

  • Stock analysis. Market Research. Industry Trends on 4000+ Stocks

  • Clean experience with
    Minimal Ads

  • Comment & Engage with ET Prime community

  • Exclusive invites to Virtual Events with Industry Leaders

  • A trusted team of Journalists & Analysts who can best filter signal from noise

Source link